Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with cancer

Source
Clinical cancer research - ISSN 1078-0432-29:3 (2023) p. 635-646

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors

Source
Frontiers in immunology - ISSN 1664-3224-13 (2022) p. 1-10
Author(s)